Who are Irinotecan liposome、5-Fluorouracil、Leucovorin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Irinotecan, 5FU, leucovorin, Irinotecan/Tegafur, Irinotecan + 5 FU + folinic acid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/irinotecan-liposome-5-fluorouracil-leucovorin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Irinotecan liposome、5-Fluorouracil、Leucovorin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Irinotecan liposome、5-Fluorouracil、Leucovorin (Irinotecan liposome、5-Fluorouracil、Leucovorin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy (topoisomerase I inhibitor + antimetabolite). Area: Oncology.

phase 3 Combination chemotherapy (topoisomerase I inhibitor + antimetabolite) Topoisomerase I; thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Irinotecan liposome、5-Fluorouracil、Leucovorin (Irinotecan liposome、5-Fluorouracil、Leucovorin) — Jiangsu HengRui Medicine Co., Ltd.. This combination regimen uses liposomal irinotecan (a topoisomerase I inhibitor) plus 5-fluorouracil and leucovorin to inhibit DNA replication and repair in cancer cells.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Irinotecan liposome、5-Fluorouracil、Leucovorin TARGET	Irinotecan liposome、5-Fluorouracil、Leucovorin	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Combination chemotherapy (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; thymidylate synthase
Irinotecan, 5FU, leucovorin	Irinotecan, 5FU, leucovorin	Asan Medical Center	marketed	Chemotherapy combination (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; thymidylate synthase
Irinotecan/Tegafur	Irinotecan/Tegafur	Sunshine Lake Pharma Co., Ltd.	phase 3	Topoisomerase I inhibitor + Fluoropyrimidine antimetabolite combination	Topoisomerase I; Thymidylate synthase
Irinotecan + 5 FU + folinic acid	Irinotecan + 5 FU + folinic acid	Pfizer	phase 3	Combination chemotherapy (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; Thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy (topoisomerase I inhibitor + antimetabolite) class)

Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Irinotecan liposome、5-Fluorouracil、Leucovorin — Competitive Intelligence Brief. https://druglandscape.com/ci/irinotecan-liposome-5-fluorouracil-leucovorin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab